Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography

Biochemical Pharmacology

Volumn 64, Issue 5-6, 2002, Pages 819-825

  Knockaert, Marie ^a   Meijer, Laurent ^a,b  

^a STATION BIOLOGIQUE   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Affinity chromatography; Cyclin dependent kinases (CDKs); Inhibitors; Paullone; Purvalanol; Selectivity

Indexed keywords

6 O CYCLOHEXYLMETHYLGUANINE; ALSTERPAULLONE; CELL EXTRACT; CINK 4; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FASCAPLYSIN; FLAVOPIRIDOL; INDIRUBIN; OLOMOUCINE; OXINDOLE; PAULLONE; PD 0183812; PKF 049 365; PNU 112455 A; PURVALANOL; QUINAZOLINE DERIVATIVE; ROSCOVITINE; STAUROSPORINE; SU 9516; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL DIVISION; CONTROLLED STUDY; DRUG SCREENING; IN VIVO STUDY; NERVOUS SYSTEM; NONHUMAN; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANIMALS; CHROMATOGRAPHY, AFFINITY; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; XENOPUS;

EID: 0036709880     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01144-9     Document Type: Article

References (38)

1. Morgan D.O. Cyclin-dependent kinases: engines clocks and microprocessors. Annu. Rev. Cell Dev. Biol. 13:1997;261-291.
2. Dunphy W.G. Cell cycle control. Methods Enzymol. 283:1997;1-678.
3. Malumbres M., Ortega S., Barbacid M. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol. Chem. 381(9/10):2000;827-838.
4. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks their cyclin activators and Cip and INK4 inhibitors. J. Mol. Biol. 287(5):1999;821-828.
5. Fischer P.M., Lane D.P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 7(12):2000;1213-1245.
6. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9(1):1999;104-111.
7. Gray N., Detivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6(9):1999;859-875.
8. Kaubisch A., Schwartz G.K. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development. Cancer J. 6(4):2000;192-212.
9. Mani S., Wang C., Wu K., Francis R., Pestell R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin. Investig. Drugs. 9(8):2000;1849-1870.
10. Meijer L. Cyclin-dependent kinases inhibitors as potential anticancer antineurodegenerative, antiviral and antiparasitic agents. Drug Resist. Update. 3(2):2000;83-88.
11. Rosania G.R., Chang Y.T. Targeting hyperproliferative disorders with cyclin-dependent kinase inhibitors. Expert Opin. Ther. Patents. 10:2000;1-16.
12. Senderowicz A.M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene. 19(56):2000;6600-6606.
13. Edamatsu H., Gau C.L., Nemoto T., Guo L., Tamanoi F. CDK inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 19(27):2000;3059-3068.
14. Park D.S., Farinelli S.E., Greene L.A. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J. Biol. Chem. 271(14):1996;8161-8169.
15. Adachi S., Ito H., Tamamori Adachi M., Ono Y., Nozato T., Abe S., Ikeda M., Marumo F., Hiroe M. Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ. Res. 88(4):2001;408-414.
16. Gil-Gomez G., Berns A., Brady H.J. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J. 17(24):1998;7209-7218.
17. Damiens E., Meijer L. Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study. Pathol. Biol. (Paris). 48(3):2000;340-351.
18. Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92(5):2000;376-387.
19. Meijer L., Thunnissen A.M., White A.W., Garnier M., Nikolic M., Tsai L.H., Walter J., Cleverley K.E., Salinas P.C., Wu Y.Z., Biernat J., Mandelkow E.M., Kim S.H., Pettit G.R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7(1):2000;51-63.
20. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.H., Lockhart D.J., Schultz P.G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281(5376):1998;533-538.
21. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. Indirubin the active constituent of a Chinese antileukaemia medicine inhibits cyclin-dependent kinases. Nat. Cell Biol. 1(1):1999;60-67.
22. Chang Y.T., Gray N.S., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6(6):1999;361-375.
23. Rosania G.R., Merlie J. Jr., Gray N., Chang Y.T., Schultz P.G., Heald R. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc. Natl. Acad. Sci. U.S.A. 96(9):1999;4797-4802.
24. Knockaert M., Gray N., Damiens E., Chang Y.T., Grellier P., Grant K., Fergusson D., Mottram J., Soete M., Dubremetz J.F., Le Roch K., Doerig C., Schultz P., Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilized inhibitors. Chem. Biol. 7(6):2000;411-422.
25. Knockaert M, Lenormand P, Gray N, Schultz P, Pouyssegur J, Meijer L. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene, in press.
26. Knockaert M, Wieking K, Schmitt S, Leost M, Mottram J, Kunick C, Meijer L. Intracellular targets of paullones: Identification by affinity chromatography using immobilized inhibitor. J Biol Chem, in press.
27. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., Meijer L., Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42(15):1999;2909-2919.
28. Zaharevitz D.W., Gussio R., Leost M., Senderowicz A.M., Lahusen T., Kunick C., Meijer L., Sausville E.A. Discovery and initial characterization of the paullones a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59(11):1999;2566-2569.
29. Leost M., Schultz C., Link A., Wu Y.Z., Biernat J., Mandelkow E.M., Bibb J.A., Snyder G.L., Greengard P., Zaharevitz D.W., Gussio R., Senderowicz A.M., Sausville E.A., Kunick C., Meijer L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267(19):2000;5983-5994.
30. Gussio R., Zaharevitz D.W., McGrath C.F., Pattabiraman N., Kellogg G.E., Schultz C., Link A., Kunick C., Leost M., Meijer L., Sausville E.A. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anticancer Drug Des. 15(1):2000;53-66.
31. Schnier J.B., Kaur G., Kaiser A., Stinson S.F., Sausville E.A., Gardner J., Nishi K., Bradbury E.M., Senderowicz A.M. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. 454(12):1999;100-104.
32. Kaiser A., Nishi K., Gorin F.A., Walsh D.A., Bradbury E.M., Schnier J.B. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys. 386(2):2001;179-187.
33. Oikonomakos N.G., Schnier J.B., Zographos S.E., Skamnaki V.T., Tsitsanou K.E., Johnson L.N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 275(44):2000;34566-34573.
34. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 38(2):2001;139-170.
35. Senderowicz A.M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia. 15(1):2001;1-9.
36. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25 two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276(1):2001;251-260.
37. Hooijberg J.H., Broxterman H.J., Heijn M., Fles D.L., Lankelma J., Pinedo H.M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 413(2):1997;344-348.
38. Hooijberg J.H., Broxterman H.J., Scheffer G.L., Vrasdonk C., Heijn M., de Jong M.C., Scheper R.J., Lankelma J., Pinedo H.M. Potent interaction of flavopiridol with MRP1a. Br. J. Cancer. 81(2):1999;269-276.